[go: up one dir, main page]

FR2848451B1 - Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee - Google Patents

Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee

Info

Publication number
FR2848451B1
FR2848451B1 FR0216017A FR0216017A FR2848451B1 FR 2848451 B1 FR2848451 B1 FR 2848451B1 FR 0216017 A FR0216017 A FR 0216017A FR 0216017 A FR0216017 A FR 0216017A FR 2848451 B1 FR2848451 B1 FR 2848451B1
Authority
FR
France
Prior art keywords
retinoid
salived
aqueous composition
composition obtained
solubilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0216017A
Other languages
English (en)
Other versions
FR2848451A1 (fr
Inventor
Agnes Ferrandis
Sandrine Orsoni
Laurent Fredon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0216017A priority Critical patent/FR2848451B1/fr
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to JP2004560489A priority patent/JP2006511547A/ja
Priority to PCT/EP2003/015041 priority patent/WO2004054543A1/fr
Priority to RU2005122467/15A priority patent/RU2005122467A/ru
Priority to BR0316892-1A priority patent/BR0316892A/pt
Priority to CA002510038A priority patent/CA2510038A1/fr
Priority to PL377430A priority patent/PL377430A1/pl
Priority to MXPA05006082A priority patent/MXPA05006082A/es
Priority to AU2003296758A priority patent/AU2003296758A1/en
Priority to KR1020057011272A priority patent/KR20050085740A/ko
Priority to EP03813148A priority patent/EP1575557A1/fr
Priority to CNA2003801066839A priority patent/CN1728983A/zh
Priority to ARP030104669A priority patent/AR042498A1/es
Publication of FR2848451A1 publication Critical patent/FR2848451A1/fr
Priority to US11/154,655 priority patent/US20050288374A1/en
Priority to ZA200505124A priority patent/ZA200505124B/en
Application granted granted Critical
Publication of FR2848451B1 publication Critical patent/FR2848451B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
FR0216017A 2002-12-17 2002-12-17 Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee Expired - Fee Related FR2848451B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0216017A FR2848451B1 (fr) 2002-12-17 2002-12-17 Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
EP03813148A EP1575557A1 (fr) 2002-12-17 2003-12-16 Procédé de stabilisation chimique d'un retinoide solubilisé dans un solvant au moyen d'une base
RU2005122467/15A RU2005122467A (ru) 2002-12-17 2003-12-16 Способ химической стабилизации собилизированного ретиноида и водная композиция, полученная этим способом, содержащая по меньшей мере один ретиноид в виде соли
BR0316892-1A BR0316892A (pt) 2002-12-17 2003-12-16 Processo para a estabilização quìmica de um retinóide solubilizado, composição aquosa, uso de uma composição, uso cosmético de uma composição e uso de uma base
CA002510038A CA2510038A1 (fr) 2002-12-17 2003-12-16 Procede de stabilisation chimique d'un retinoide solubilise dans un solvant au moyen d'une base
PL377430A PL377430A1 (pl) 2002-12-17 2003-12-16 Sposób chemicznej stabilizacji solubilizowanego retinoidu w rozpuszczalniku z wykorzystaniem zasady
MXPA05006082A MXPA05006082A (es) 2002-12-17 2003-12-16 Proceso para la estabilizacion quimica de un retinoide solubilizado en un solvente usando una base.
AU2003296758A AU2003296758A1 (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
JP2004560489A JP2006511547A (ja) 2002-12-17 2003-12-16 塩基を使用する、溶媒中における可溶化レチノイドの化学的安定化方法
PCT/EP2003/015041 WO2004054543A1 (fr) 2002-12-17 2003-12-16 Procede de stabilisation chimique d'un retinoide solubilise dans un solvant au moyen d'une base
CNA2003801066839A CN1728983A (zh) 2002-12-17 2003-12-16 用碱使增溶视黄类化合物在溶剂中的化学稳定方法
KR1020057011272A KR20050085740A (ko) 2002-12-17 2003-12-16 염기를 이용하여 용매 내에서 가용화된 레티노이드를화학적으로 안정화시키는 방법
ARP030104669A AR042498A1 (es) 2002-12-17 2003-12-17 Procedimiento de estabilizacion quimica de un retinoide solubilizado y composicion obtenida de acuerdo con el procedimiento que comprende al menos un retinoide en forma salificada
US11/154,655 US20050288374A1 (en) 2002-12-17 2005-06-17 Chemical stabilization of solubilized retinoids and aqueous compositions comprised thereof
ZA200505124A ZA200505124B (en) 2002-12-17 2005-06-24 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0216017A FR2848451B1 (fr) 2002-12-17 2002-12-17 Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee

Publications (2)

Publication Number Publication Date
FR2848451A1 FR2848451A1 (fr) 2004-06-18
FR2848451B1 true FR2848451B1 (fr) 2007-01-12

Family

ID=32338901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0216017A Expired - Fee Related FR2848451B1 (fr) 2002-12-17 2002-12-17 Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee

Country Status (4)

Country Link
CN (1) CN1728983A (fr)
AR (1) AR042498A1 (fr)
FR (1) FR2848451B1 (fr)
ZA (1) ZA200505124B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2991176B1 (fr) * 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide solubilise, de type gel hydroglycolique
US9244054B2 (en) * 2012-07-10 2016-01-26 GM Global Technology Operations LLC Systems and methods for determining a state of deterioration of engine oil using multiple preselected oil properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601670B1 (fr) * 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
FR2647015B1 (fr) * 1989-05-17 1994-05-06 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
JP4061015B2 (ja) * 2000-10-30 2008-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物

Also Published As

Publication number Publication date
FR2848451A1 (fr) 2004-06-18
AR042498A1 (es) 2005-06-22
ZA200505124B (en) 2007-03-28
CN1728983A (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
PL370779A1 (en) Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
WO2006017055A3 (fr) Derives de pyrazole amide, compositions contenant de tels composes et procedes d'utilisation
SI1605932T1 (sl) Intranazalna formulacija rotigotina
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
FR08C0052I2 (fr) Derives de 6-mercapto-cyclodextrine: agents d'inversion du blocage neuromusculaire provoque par des substances medicamenteuses
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
DE60118067D1 (de) Pharmazeutische Zusammensetzung mit Dystrophin Exon 45 zur Behandlung von Duchenne-Muskeldystrophie
IT1304501B1 (it) Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
EP2085086A3 (fr) methode pour le traitement d'une insuffisance cardiaque congestive ou de la nephropathie diabétique
EP2338886A3 (fr) Dérivés de naphtalene
HUP0401160A3 (en) 2,4,5-trisubstituted thiazolyl derivatives having antiinflammatory activity, process for their preparation and pharmaceutical compositions containing them
EP2168962A3 (fr) Phénylacétamides et leur utilisation en tant que modulateurs de la glucokinase
ES2132190T3 (es) Complejo de ciclodextrina.
DK1087934T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
MA25827A1 (fr) Derives de benzoylpyridine ou son sel, fongicide le contenant en tant qu'ingredient actif, son procede de production et intermediaire pour le produire.
BG106681A (en) Solutions containing epinastine
DZ3156A1 (fr) Nouvelle forme polymorphe du sel d'acide 5-Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione, maleique.
KR910000620A (ko) N-치환 라우르아미드, 그의 제조방법 및 조성물
EP1133979A3 (fr) Utilisation de corps gras particuliers permettant de modifier les propriétés physico-chimiques de la peau et/ou des muqueuses en tant qu'agents empêchant ou diminuant l'adhésion des micro-organismes sur ces dernières
FR2848451B1 (fr) Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
EP0952159A3 (fr) Utilisation des dérivés de somatostatine et/ou des dérivés de phénylhydrazone en tant qu'agents anti-inflammatoires ou analgésiques
EP2044958A3 (fr) Composition pharmaceutique pour traiter l'artériosclérose
FR2823992B1 (fr) Dispersions d'hydroxyapatite comprenant un acide amine en tant qu'agent stabilisant, et leur procede de preparation
DE60115997D1 (de) 1,1- and 1,2-Disubstituierte Cyclopropane, Verfahren zu deren Herstellung und deren pharmazeutischen Zusammensetzungen
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20090831